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Abstract: Lyssaviruses constitute a diverse range of viruses with the ability to cause fatal encephalitis
known as rabies. Existing human rabies vaccines and post exposure prophylaxes (PEP) are based on
inactivated preparations of, and neutralising antibody preparations directed against, classical rabies
viruses, respectively. Whilst these prophylaxes are highly efficient at neutralising and preventing a
productive infection with rabies virus, their ability to neutralise other lyssaviruses is thought to be
limited. The remaining 15 virus species within the lyssavirus genus have been divided into at least
three phylogroups that generally predict vaccine protection. Existing rabies vaccines afford protection
against phylogroup I viruses but offer little to no protection against phylogroup II and III viruses.
As such, work involving sharps with phylogroup II and III must be considered of high risk as no
PEP is thought to have any effect on the prevention of a productive infection with these lyssaviruses.
Whilst rabies virus itself has been characterised in a number of different animal models, data on the
remaining lyssaviruses are scarce. As the lyssavirus glycoprotein is considered to be the sole target
of neutralising antibodies we generated a vaccine strain of rabies using reverse genetics expressing
highly divergent glycoproteins of West Caucasian Bat lyssavirus and Ikoma lyssavirus. Using
these recombinants, we propose that recombinant vaccine strain derived lyssaviruses containing
heterologous glycoproteins may be a suitable surrogate for wildtype viruses when assessing vaccine
protection for the lyssaviruses.
Keywords: lyssavirus; rabies; vaccine; neutralizing antibody; chimera; antigenic
1. Introduction
The lyssavirus genus is a group of high consequence pathogens with, following the onset of
clinical disease, a near 100% fatality rate. Rabies virus (RABV), the prototype lyssavirus, causes
over 59,000 human deaths annually, with the majority of the fatalities being in Africa and Asia [1].
This figure is believed to be a gross underestimate as a large proportion of rabies deaths occur in
resource limited areas that lack medical facilities and adequate reporting systems to record human
cases of rabies [2,3]. Further, in endemic areas, diagnostic capabilities are also often lacking and as
such syndromic assessment is used to determine rabies, often with patients showing symptoms of
disease being sent home to die [3,4]. Despite the burden of this horrific disease, rabies continues to be
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considered a neglected tropical disease with little support available in the majority of endemic regions
to try and reduce the burden of disease [5].
RABV is just one member of a divergent genus of viruses that are all thought capable of causing
fatal encephalitis in any infected mammal [5]. The main mode of transmission is through mechanical
transfer, most often following the bite of an infected dog. However, interestingly these pathogens
have been isolated across the globe from a variety of mammalian species with 14 of the 16 proposed
lyssavirus species being detected in bats [6]. Interestingly, only non-rabies lyssaviruses have been
detected in bats across the Old World with bat rabies virus being apparently restricted to the New
World [7]. Despite this, rabies in terrestrial mammals has been detected globally with very few
isolations of lyssaviruses in terrestrial species and no evidence of sustained lyssavirus transmission in
terrestrial carnivores [8].
Within this genus, the 16 recognized lyssavirus species are genetically and antigenically divided
into phylogroups that generally dictate the ability of rabies vaccines to afford protection. Serological
responses to RABV vaccination are measured by quantitating the neutralisation of virus using test
sera through comparison with neutralisation by control sera. All human rabies vaccines are based on
inactivated preparations of whole virus. The response to vaccination can differ between individuals but
it is widely accepted that the protective cut off for serological positivity and protection against RABV
is 0.5 international units (IU)/mL [9]. Phylogroup I includes the classical RABVs alongside Aravan
lyssavirus (ARAV), Australian bat lyssavirus (ABLV), Bokeloh bat lyssavirus (BBLV), Duvenhage
lyssavirus (DUVV), European bat-1 and -2 lyssaviruses (EBLV-1 and EBLV-2), Irkut lyssavirus (IRKV),
Khujand lyssavirus (KHUV), and Gannoruwa bat lyssavirus (GBLV). Studies with some of these
phylogroup I viruses have demonstrated that a serological titre of 0.5 IU/mL is not sufficient for
protection but that higher titres can neutralise [10–14]. In contrast, the antibody response generated by
vaccination is generally considered to be insufficient to confer protection against the more genetically
and antigenically divergent lyssaviruses. Phylogroup II encompasses the African Lyssaviruses, and
includes Lagos bat lyssavirus (LBV-lineages A-D), Mokola lyssavirus (MOKV), and Shimoni bat
lyssavirus (SHIBV) whilst even more divergent viruses have been proposed as belonging to phylogroup
III [15] and include West Caucasian bat lyssavirus (WCBV), Ikoma lyssavirus (IKOV) and Lledia
bat lyssavirus (LLEBV) [16]. In vivo vaccination-challenge experiments have shown reduced or no
efficacy of current licensed rabies vaccines against viruses in phylogroup II (MOKV, LBV, SHIBV) [12],
phylogroup III (WCBV) [10,17] and the most divergent lyssavirus characterised to date, IKOV. Where
available, interactions between viruses and sera have been quantitated using antigenic cartography
and have reiterated the antigenic distances between the three phylogroups [18].
As the target for neutralising antibody responses against all lyssaviruses is the surface glycoprotein
(G) [19], the glycoproteins from divergent lyssaviruses were swapped into a vaccine backbone to enable
vaccination challenge experiments to be performed with reduced risk to the operator and without
compromising experimental outputs assessing serological protection from vaccination. Here we
describe the generation of recombinant rabies vaccine strain viruses containing divergent glycoproteins
and demonstrate their utility in vaccination challenge experimentation with reduced risk to the
operator. The exchange of glycoproteins was tolerated in vitro with peak titres being comparable to
previous reports with wildtype viruses [17]. In vivo, a lack of protection from existing vaccines was
demonstrated in mice that had been vaccinated with rabies vaccines and challenged with the chimeric
viruses. Furthermore, peripheral inoculation with the chimeric viruses resulted in survivorship
indicating that these recombinants may exhibit reduced pathogenicity when compared to wildtype
viruses although further assessments of wildtype viruses is warranted. These chimeric viruses may be
considered as an alternative option for studying RABV vaccine protection against highly divergent
lyssaviruses in vivo as their pathogenicity may be reduced.
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2. Materials and Methods
2.1. Full Length Plasmid Construction
The rabies vaccine strain (SN) reverse genetics DNA backbone was utilised for all recombinant
virus genome clone assembly. The SN strain is based on the street Alabama Dufferin (SAD) B19 vaccine
strain of rabies as described previously [20–24]. Constructs were generated by exchanging the vaccine
strain G with that of the highly divergent West Caucasian Bat virus G and the Ikoma virus G (Figure S1).
The parent homologous cSN strain was rescued and characterised alongside the recombinant viruses.
Restriction endonuclease (REs) sites, HpaI and NheI (Promega, Madison, WI, USA) were utilised to
facilitate exchange of the G open reading frames (ORFs). The recombinant G ORFs were amplified,
using primers that incorporate the respective RE sites, from total cellular RNA from lyssavirus infected
cells (WCBV G transfer into FL HpaI For: 5′ TATATATAGTTAACAAGATGGCTTCCTACTTTGC
3′; WCBV G transfer into FL NheI Rev: 5′ TATATATAGTCAGCACCTTGTTATTGGGCAGTTTGTC;
IKOV G transfer into FL HpaI For: 5′ TATATATAGTTAACAAGATGGCTCAGTTGGTCAC 3′; IKOV
G transfer into FL NheI Rev: 5′ TATATATAGTCAGCAACCCACTAGAATGCAGAACTCTTG 3′).
Following digestion, gel purification, ligation, and transformation, clones were checked by restriction
enzyme digestion and plasmid sequencing prior to virus rescue.
2.2. Virus Rescue, Titration, and Growth Curves
Virus rescue was performed within SAPO4/ACDP3 biocontainment facilities as described
previously [21,25] using fowlpox T7 (FPT7) to provide sufficient T7 RNA polymerase. Baby Hamster
Kidney cells (BHKs) were infected with FPT7 at a multiplicity of infection (moi) of 0.01 for 1 h at 37 ◦C
before washing the cells with Phosphate Buffered Saline (pH 7.2) and transfecting each well with: 1 µg
of pN, 1 µg of pP, 1 µg of pL and 2 µg of genome plasmid using FuGENE6 (Promega). Plates were
incubated for 48–72 h at 37 ◦C prior to assessing if virus rescue had occurred by fixation and staining
fixed cells with FITC conjugated anti-N antibodies (Fujirebio, Malvern, PA, USA). Where successful
rescue events were observed, virus was passaged on BHKs until 100% infectivity was reached and
titrated as previously described [20]. Virus titres were determined as focus forming units per mL
(ffu/mL). Multistep growth curves were conducted as previously described [21]. To generate growth
curves, 100 µL of supernatant was harvested and frozen at−80 ◦C for each time point required. Viruses
were thawed and titrated in triplicate on BHK cells to determine titres at each time point.
2.3. In Vivo Experimentation
All in vivo experimentation was carried out within ACDP3/SAPO4 biocontainment facilities
at the Animal and Plant Health Agency (APHA), Weybridge, UK. Mouse experimentation was
undertaken in accordance with strict Home Office regulations under the Animals in Scientific
Procedures Act (1986) under HO project license PPL70/7394. All experimentation was reviewed
internally by the APHA Animal Welfare in Experimental Research Board (AWERB) prior to initiation.
All naïve animals were sourced from licensed and registered breeder within the UK. All animals were
given access to food and water ad libitum throughout all experimentation and animals were checked
at least twice daily to assess welfare and the development of clinical disease.
Three to four week old CD1 mice were purchased (Charles River, Wilmington, MA, USA) and
microchipped using Trovan chips to enable identification. Mice were vaccinated using the human rabies
vaccine VeroRAB (Novartis, Basel, Switzerland) at a 1 in 20 in sterile filtered deionised water following
reconstitution as per the manufacturer’s instructions. Mice were vaccinated via the intraperitoneal
route with 0.5 mL of diluted vaccine to the lower right hand quadrant of the abdomen on days 0
and 14. Mock vaccinated animals were included for each challenge group to ensure the validity
of the challenge virus. At 21 days post vaccination, the dorsal tail vein of each mouse was nicked
under anaesthesia using a scalpel blade and blood was collected in CB300 tubes (Sarstedt, Hampton,
NH, USA). Following collection, blood samples were stored at 4 ◦C overnight prior to centrifugation
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at 2500 rpm (860× g) for 10 min and serum separated from the blood pellet. Serum samples were heat
inactivated at 56 ◦C for 30 min and stored at −20 ◦C until required.
Naïve mice were challenged intracranially (IC) with 100 ffu/30 µL of infectious recombinant virus.
Following infection, mice were checked twice daily and clinical scores were recorded for each mouse
according to an established clinical score system with defined humane end points [26]. For assessment
of peripheral pathogenicity, mice were inoculated into the left hind footpad (FP) with 1000 ffu/50 µL.
Mice were monitored for 28 days post infection. Results are only shown for 12 days for clarity as no
further animals succumbed during the remainder of the experiment. Clinical signs were scored and
mice terminated as described [26]. The humane endpoint for termination and cervical dislocation was
a clinical score of 3. Mice were cardiac bled under terminal anaesthesia prior to termination.
2.4. Serology
At 21 days post vaccination, mice were tail bled for assessment of seroconversion to vaccine. Each
serum sample was run on a partial dilution series using a rabies pseudotype neutralisation assay (PNA)
as described previously [27] ranging from a 1 in 20 to 1 in 640 dilution, due to the limited volume of
serum. This enabled determination of whether the mice had seroconverted to a titre comparable to the
WHO standard 0.5 IU/mL serum. Following the duration of the challenge experimentation mice were
cardiac bled under terminal anaesthesia and sera assessed by fluorescent antibody virus neutralization
(FAVN) and modified (m) FAVN as described previously [11,18].
3. Results
Following rescue, cSN-IKOV reached 100% infection at passage 6 and cSN-WCBV by passage 7.
The final passage of the rescued virus was compared with the original clone and no mutations were
detected. The peak titres of the recombinant viruses reached titres comparable to previously generated
recombinants that used the same vaccine backbone with the heterologous G from the European
bat lyssaviruses (EBLVs) [21]. Growth curves showed a reduction in growth kinetics compared
but recombinant viruses were viable and grew successfully (Figure 1). The wildtype WCBV was
unavailable for comparison and so the chimeras were compared against the parent cSN vaccine and
the IKOV wildtype virus. There was a notable difference between the growth curve of wildtype
cSN and the recombinant viruses (Figure 1). The wildtype vaccine cSN strain grew to a peak titre of
8.35 × 108 ffu/mL at 72 h post infection (hpi) whilst wildtype IKOV grew to 3.6 × 106 ffu/mL after
96 h. The peak titre of the next most successful virus; cSN-WCBV-G was 2.92 × 105 ffu/mL at 96 hpi.
All viruses were detectable by 18 hpi. The end point titre of cSN-IKOV-G was 5.33 × 104 ffu/mL,
2 logs lower than the wildtype IKOV. The growth patterns of each virus also differed. The growth
of cSN had plateaued by 96 hpi. In contrast cSN-WCBV-G and cSN-IKOV-G both appeared to be
increasing in titre over time as both peaked at 96 hpi. This may indicate a retarded growth rate of these
two recombinants.
The degree of protection afforded by a human rabies vaccine to the recombinant viruses was then
assessed in vivo. Blood collected from vaccinated mice were used in a pseudotype neutralisation assay.
The WHO control serum sample had a reciprocal titre of 639.99 on the PNA. The mock vaccinated pool
1 had a titre of 79.99 and the mock vaccinated pool 2 had a titre of just 11.31 indicating that none of
these mock vaccinated mice had seroconverted. From the vaccinated mice, four mice seroconverted to
the same titre as the WHO control; 639.99 with the remainder having even higher titres (>905.09).
Two groups of 10 vaccinated mice and 5 mock vaccinated mice were challenged, at day 28 post
vaccination, via the IC route with 100 ffu/mL of virus in 30 µL. Mice could not be challenged with
wildtype WCBV as this isolate was not available to us. Infection with the wildtype IKOV had already
been assessed and as such peripheral pathogenicity with this isolate was not assessed in this study [17].
All unvaccinated mice challenged IC with cSN, cSN-WCBV-G, or cSN-IKOV-G succumbed by day
6 or 7 (Figure 2a). From the groups of vaccinated mice, all those challenged IC with cSN survived
challenge whilst those challenged with cSN-WCBV-G had to be terminated by day 7. In addition, 90%
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of the cSN-IKOV-G infected mice were terminated on day 7 and the remaining mouse was terminated
with clinical disease that had reached the humane endpoint by day 8 (Figure 2b). To assess peripheral
pathogenicity, each of the recombinant viruses was inoculated peripherally as described into naïve
mice. With the exception of two cSN-IKOV-G inoculated mice that developed clinical disease and were
humanely terminated on day 8, all mice survived to the end of the study (Figure 3).
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4. Discussion
Novel lyssaviruses continue to be discovered globally. With the increasing recog ition of the
importance of bats as reservoirs of zoonotic pathogens, the popularity of leisure activities that facilitate
human interactions with bats (e.g., caving, potholing, speleology), and the ongoing encroachment of
humans into wild areas, the investigation of bat borne zoonotic pathogens is of relevance to human
and animal health. For lyssaviruses, the zoonotic threat from bats is heightened as although not readily
transmitted, where infection does occur an clinic l disease develops, lyssavirus infection is invariably
fatal. A further risk from these pathogens is through the potential for occupational exposure. Although
lyssaviruses are principally spread through the bite of an infected animal, rare exposures including via
the aerosol route and through exposed mucous membranes have been reported following laboratory
or nosocomial infections [28,29]. In the laboratory, the potential for a needle stick injury exists and as
such work with highly divergent lyssaviruses is limited to esse tial procedures. To this end, we used
reverse genetics to evaluate recombinant virus s c taining diverge t l roteins as surrogates for
wildtype viruses as an alternative to using wildtype lyssaviruses of undefined human pathogenicity in
vaccination challenge experimentation. Construction and rescue of recombinant viruses based on the
cSN (SAD-B19) vaccine strain of rabies enabled the generation of viruses containing glycoproteins of
WCBV and IKOV. Existing rabies accines are not generally considere able to induce neutralising
antibodies that can effectively protect against these viruses and as such th attempted d velopment of
a potentially bio-safe alternative is warranted. This approach has further demonstrated that where
live virus isolates are not available, as was the situation with WCBV in this study, gene synthesis can
be used to make a recombinant virus expressing the glycoprotein. The study also demonstrated that
homologous M and G are seemingly not necessary for successful virus rescue even where interactions
between highly divergent proteins are required. Certainly, swapping t e G alone from div rgent viruses
into a vacc e strain backbone demonstrated t at homolog us M and G proteins were not required
for virus rescue. The most recently described Lleida Bat Lyssavirus (LLEBV) was not investigated
as part of this study as the sequence of the G was not available although more recently it has been
defined [30] and as such further work may include assessment of LLEBV G in a similar system [16].
From a neutralisation perspective, these chimeric viruses have great utility in assessment of in vitro
serological neutralisation although sera specific for each virus is necessary to thoroughly investigate
the cross reactivity of antibody responses to different lyssavirus species. Other studies have suggested
a utility in pseudotype viruses although neutralisation profiles are often inflated using this approach
as the surrogates do not necessarily reflect outcomes with live viruses [31].
Initially, virus rescue and in vitro replication was assessed. Whilst the growth of the parent cSN
vaccine strain was clearly greater than that of the two chimeras generated, their peak titres were similar
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to that observed for other lyssaviruses where the generation of high titre virus stocks is considered to
be problematic [21]. The peak titre achieved for cSN-IKOV was lower than observed for wildtype IKOV
suggesting that the recombinants are likely attenuated compared to wildtype viruses as expected.
Where elements of divergent lyssaviruses are swapped into heterologous backbones the effect of
having heterologous M and G proteins is of interest. Certainly, it has been shown for a number of
Mononegavirales including respiratory syncytial virus, influenza, and vesicular stomatitis virus that
M interacts directly with G to enable high efficiency viral budding from host cells [32–34]. For rabies,
the interaction between G and M enables efficient budding of viral particles [35] with the interacting
domain residing in the cytoplasmic domain of G [32,36]. Indeed, the lyssavirus M protein regulates the
viral life cycle, inhibiting transcription and even stimulating replication when supplied in trans [37].
Further, the replacement of non-pathogenic M proteins with those from pathogenic strains has resulted
in an increase in virulence [38]. This effect was also demonstrated whereby a significant increase in
pathogenicity was demonstrated when including homologous M and G [24]. Critically, studies have
demonstrated that the exchange of G ectodomains alone between lyssaviruses enables virus rescue [36].
In contrast, in the present study, rescue is tolerated where complete G ORFs are exchanged with
little effect on replicative ability in vitro even where exchanges are made between the most divergent
lyssaviruses. Different studies have demonstrated that other lyssavirus G proteins can be swapped
into the cSN backbone with similar outputs [21] although these studies assessed lyssaviruses more
closely related to RABV with a greater degree of sequence identity in G. The process by which protein
structures affect these interactions cannot be concluded although the conservation seen across the
lyssavirus M protein at least suggests that this group of viruses have evolved with similar drivers for
genetic conservation.
From the in vivo studies, data from the survival curves indicated some substantial differences
between survivorship in intracranially challenged vaccinated and unvaccinated individuals. It has
been previously reported that cSN is pathogenic when inoculated via the IC route but is considered
to be apathogenic following peripheral inoculation [21]. All unvaccinated mice challenged IC with
cSN were terminated with clinical disease by 7 dpi whereas all vaccinated mice challenged with
these viruses survived as expected [11]. The development of clinical disease in mice infected with
cSN-WCBV-G and cSN-IKOV-G, either those previously vaccinated or mock vaccinated, confirms the
pathogenic role of the G proteins and supports existing data describing a lack of protection against
divergent lyssaviruses from vaccine induced immunity [10]. Both vaccinated and unvaccinated mice
challenged IC with cSN-WCBV-G developed clinical disease, being humanely terminated at 7 dpi.
The same outcome was observed with the cSN-IKOV-G IC infected mice with all unvaccinated mice
developing clinical disease and being terminated by day 6 post infection. Further, 90% of the vaccinated
mice were terminated with clinical disease by 7 dpi with the remaining 10% developing clinical disease
that required termination by 8 dpi. This confirmed the lack of protection afforded by rabies vaccines
against these divergent lyssaviruses and mimics in vitro data suggesting that strong neutralising
antibodies induced by the rabies vaccines are unable to neutralise these viruses.
The peripheral infection of naïve mice with cSN, cSN-WCBV-G, and cSN-IKOV-G demonstrated a
lack of pathogenicity of all viruses following peripheral inoculation with the exception of 40% (n = 2/5)
of the cSN-IKOV-G mice that developed clinical disease by day 8 and had to be humanely terminated
suggesting that a degree of pathogenicity is conferred by the IKOV G protein. Few studies assessing
pathogenicity of WCBV and IKOV have been reported. For WCBV, inoculation of the big brown bat
(Eptesicus fuscus) demonstrated that infection via the oral route was non-viable with no clinical or
serological response being detected and peripheral inoculation into the masseter muscle causing only
a serological response. In contrast, clinical disease developed in bats inoculated with virus in the
musculature of the neck with 57% succumbing to infection and the remainder generating a serological
response demonstrating exposure [39].
For IKOV, murine studies have shown that both peripheral and IC inoculation of wildtype IKOV
causes clinical disease. Interestingly, whilst neat (104.8TCID50/mL) IC inoculation and peripheral
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inoculation caused 100% mortality, a detectable dose effect was reported following intramuscular
infection with a 10-fold dilution of IKOV with only 40% of mice infected peripherally succumbing
to infection [17]. The lower dose used in this study equates to an inoculation of approximately 190
infectious particles. In comparison, in this study infection with a higher dose of 1000 ffu/50 µL led
to fewer animals developing clinical disease and as such it is reasonable to conclude that the vaccine
expressing the IKOV G may be less pathogenic than the wildtype virus, especially when considering
the growth curve data whereby the recombinant virus growth kinetics were retarded when compared
with the cSN virus and the IKOV wildtype isolate. Regardless, the effect of route of inoculation requires
further assessment and ideally an assessment of peripheral pathogenicity with divergent wildtype
viruses is warranted. A minimal dose for infection with lyssaviruses has not been defined although it
has to be assumed that if a single virion enters a nerve and establishes infection then this is sufficient
to cause disease. Certainly, effects of dose have been assessed, and titrating out virus can lead to a
reduction in pathogenicity. Previous murine and chiropteran studies that titrated out lyssaviruses to
assess the outcomes of multiple exposures to low doses of virus demonstrated the effect of dose [40,41].
However, in contrast, other bat models of infection have demonstrated less survivorship where low
doses of virus are inoculated for some lyssaviruses [42–44]. Some standardisation of challenge models
would enable better comparison between experiments with these viruses.
As described, the use of recombinant chimeric viruses as a substitute for wildtype lyssaviruses for
in vivo vaccination challenge experimentation may represent an alternative option to wildtype viruses
that may even reduce operator risk from these lethal viruses. The opportunity to utilise such constructs
as vehicles for vaccine development may also be of future use as it is likely that the expression of the
divergent glycoprotein is sufficient to generate a neutralising immune response that may be protective
against the chosen glycoprotein. Certainly, whilst the neutralising antibody response to vaccination
is understood to be the key to protective immunity, the cell mediated responses to elements of the
viral particle other than the glycoprotein requires further interrogation, and such recombinants may
aide that. Further assessment of such constructs, including mutagenesis of residues within G that are
associated with viral pathogenesis, could also extend these studies [20,45–48]. Finally, the observation
that gene swaps between highly divergent lyssaviruses are tolerated may influence the future direction
of research assessing these high-risk pathogens for which no vaccine protection or post exposure tools
are available.
Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/10/3/130/s1,
Figure S1: Schematic of full length plasmids constructed containing heterologous glycoproteins. The recombinant
DNA clones of each genome are shown with the glycoprotein being swapped to contain divergent G proteins in
place of the wildtype protein. Restriction enzymes utilised to swap each gene are labelled.
Acknowledgments: This study was funded by DEFRA grant SE0426 and SE0431 and by the European Union’s
Horizon 2020 research and innovation programme under RABYD-VAX grant agreement No 733176. The funders
had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Jennifer S. Evans was supported in a PhD studentship through SE0426.
Author Contributions: Ashley C. Banyard and Jennifer S. Evans conceived and designed the experiments;
Jennifer S. Evans, Guanghui Wu, David Selden, Hubert Buczkowski, Ashley C. Banyard and Leigh Thorne
performed the experiments; Jennifer S. Evans, Anthony R. Fooks, Guanghui Wu and Ashley C. Banyard analyzed
the data; Ashley C. Banyard wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Fooks, A.R.; Banyard, A.C.; Horton, D.L.; Johnson, N.; McElhinney, L.M.; Jackson, A.C. Current status of
rabies and prospects for elimination. Lancet 2014, 384, 1389–1399. [CrossRef]
2. Hampson, K.; Coudeville, L.; Lembo, T.; Sambo, M.; Kieffer, A.; Attlan, M.; Barrat, J.; Blanton, J.D.; Briggs, D.J.;
Cleaveland, S.; et al. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis. 2015,
9, e0003709.
Viruses 2018, 10, 130 9 of 11
3. Banyard, A.C.; Horton, D.; Freuling, C.; Müller, T.; Fooks, A.R. Control and prevention of canine rabies:
The need for building laboratory based surveillance capacity. Antivir. Res. 2013, 98, 357–364. [CrossRef]
[PubMed]
4. Mani, R.S.; Anand, A.M.; Madhusudana, S.N. Human rabies in India: An audit from a rabies diagnostic
laboratory. Trop. Med. Int. Health 2016, 21, 556–563. [CrossRef] [PubMed]
5. Rupprecht, C.; Kuzmin, I.; Meslin, F. Lyssaviruses and rabies: Current conundrums, concerns, contradictions
and controversies. F1000Res. 2017, 6. [CrossRef] [PubMed]
6. Banyard, A.C.; Fooks, A.R. The impact of novel lyssavirus discovery. Microbiol. Aust. 2017, 38, 18–21.
[CrossRef]
7. Banyard, A.C.; Evans, J.S.; Luo, T.R.; Fooks, A.R. Lyssaviruses and bats: Emergence and zoonotic threat.
Viruses 2014, 6, 2974–2990. [CrossRef] [PubMed]
8. Streicker, D.G.; Turmelle, A.S.; Vonhof, M.J.; Kuzmin, I.V.; McCracken, G.F.; Rupprecht, C.E. Host phylogeny
constrains cross-species emergence and establishment of rabies virus in bats. Science 2010, 329, 676–679.
[CrossRef] [PubMed]
9. Moore, S.M.; Hanlon, C.A. Rabies-specific antibodies: Measuring surrogates of protection against a fatal
disease. PLoS Negl. Trop. Dis. 2010, 4, e595. [CrossRef] [PubMed]
10. Hanlon, C.A.; Kuzmin, I.V.; Blanton, J.D.; Weldon, W.C.; Manangan, J.S.; Rupprecht, C.E. Efficacy of rabies
biologics against new lyssaviruses from Eurasia. Virus Res. 2005, 111, 44–54. [CrossRef] [PubMed]
11. Brookes, S.M.; Healy, D.M.; Fooks, A.R. Ability of rabies vaccine strains to elicit cross-neutralising antibodies.
Dev. Biol. (Basel) 2006, 125, 185–193. [PubMed]
12. Badrane, H.; Bahloul, C.; Perrin, P.; Tordo, N. Evidence of two Lyssavirus phylogroups with distinct
pathogenicity and immunogenicity. J. Virol. 2001, 75, 3268–3276. [CrossRef] [PubMed]
13. Nolden, T.; Banyard, A.C.; Finke, S.; Fooks, A.R.; Hanke, D.; Hoper, D.; Horton, D.L.; Mettenleiter, T.C.;
Muller, T.; Teifke, J.P.; et al. Comparative studies on the genetic, antigenic and pathogenic characteristics of
Bokeloh bat lyssavirus. J. Gen. Virol. 2014, 95, 1647–1653. [CrossRef] [PubMed]
14. Fekadu, M.; Shaddock, J.H.; Sanderlin, D.W.; Smith, J.S. Efficacy of rabies vaccines against Duvenhage virus
isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses. Vaccine
1988, 6, 533–539. [CrossRef]
15. Kuzmin, I.V.; Niezgoda, M.; Franka, R.; Agwanda, B.; Markotter, W.; Beagley, J.C.; Urazova, O.Y.;
Breiman, R.F.; Rupprecht, C.E. Possible emergence of West Caucasian bat virus in Africa. Emerg. Infect. Dis.
2008, 14, 1887–1889. [CrossRef] [PubMed]
16. Arechiga Ceballos, N.; Vazquez Moron, S.; Berciano, J.M.; Nicolas, O.; Aznar Lopez, C.; Juste, J.;
Rodriguez Nevado, C.; Aguilar Setien, A.; Echevarria, J.E. Novel lyssavirus in bat, Spain. Emerg. Infect. Dis.
2013, 19, 793–795. [CrossRef] [PubMed]
17. Horton, D.L.; Banyard, A.C.; Marston, D.A.; Wise, E.; Selden, D.; Nunez, A.; Hicks, D.; Lembo, T.;
Cleaveland, S.; Peel, A.J.; et al. Antigenic and genetic characterization of a divergent African virus, Ikoma
lyssavirus. J. Gen. Virol. 2014, 95, 1025–1032. [CrossRef] [PubMed]
18. Horton, D.L.; McElhinney, L.M.; Marston, D.A.; Wood, J.L.; Russell, C.A.; Lewis, N.; Kuzmin, I.V.;
Fouchier, R.A.; Osterhaus, A.D.; Fooks, A.R.; et al. Quantifying antigenic relationships among the
Lyssaviruses. J. Virol. 2010. [CrossRef] [PubMed]
19. Gaudin, Y.; Ruigrok, R.W.; Tuffereau, C.; Knossow, M.; Flamand, A. Rabies virus glycoprotein is a trimer.
Virology 1992, 187, 627–632. [CrossRef]
20. Faber, M.; Pulmanausahakul, R.; Nagao, K.; Prosniak, M.; Rice, A.B.; Koprowski, H.; Schnell, M.J.;
Dietzschold, B. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness.
Proc. Natl. Acad. Sci. USA 2004, 101, 16328–16332. [CrossRef] [PubMed]
21. Marston, D.A.; McElhinney, L.M.; Banyard, A.C.; Horton, D.L.; Nunez, A.; Koser, M.L.; Schnell, M.J.;
Fooks, A.R. Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein. J. Gen. Virol.
2013, 94, 284–292. [CrossRef] [PubMed]
22. McGettigan, J.P.; Foley, H.D.; Belyakov, I.M.; Berzofsky, J.A.; Pomerantz, R.J.; Schnell, M.J. Rabies virus-based
vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong,
cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.
J. Virol. 2001, 75, 4430–4434. [CrossRef] [PubMed]
Viruses 2018, 10, 130 10 of 11
23. Morimoto, K.; Foley, H.D.; McGettigan, J.P.; Schnell, M.J.; Dietzschold, B. Reinvestigation of the role of the
rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J. Neurovirol. 2000, 6,
373–381. [CrossRef] [PubMed]
24. Pulmanausahakul, R.; Li, J.; Schnell, M.J.; Dietzschold, B. The glycoprotein and the matrix protein of rabies
virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. J. Virol. 2008, 82,
2330–2338. [CrossRef] [PubMed]
25. Schnell, M.; Mebatsion, T.; Conzelmann, K.-K. Infectious rabies virus from cloned cDNA. EMBO J. 1994, 13,
4195–4203. [PubMed]
26. Healy, D.M.; Brookes, S.M.; Banyard, A.C.; Nunez, A.; Cosby, S.L.; Fooks, A.R. Pathobiology of rabies virus
and the European bat lyssaviruses in experimentally infected mice. Virus Res. 2013, 172, 46–53. [CrossRef]
[PubMed]
27. Wright, E.; Temperton, N.J.; Marston, D.A.; McElhinney, L.M.; Fooks, A.R.; Weiss, R.A. Investigating antibody
neutralization of lyssaviruses using lentiviral pseudotypes: A cross-species comparison. J. Gen. Virol. 2008,
89, 2204–2213. [CrossRef] [PubMed]
28. Winkler, W.G.; Fashinell, T.R.; Leffingwell, L.; Howard, P.; Conomy, P. Airborne rabies transmission in a
laboratory worker. JAMA 1973, 226, 1219–1221. [CrossRef] [PubMed]
29. Basavaraju, S.V.; Kuehnert, M.J.; Zaki, S.R.; Sejvar, J.J. Encephalitis caused by pathogens transmitted through
organ transplants, United States, 2002-2013. Emerg. Infect. Dis. 2014, 20, 1443. [CrossRef] [PubMed]
30. Marston, D.A.; Ellis, R.; Wise, E.; Aréchiga-Ceballos, N.; Freuling, C.; Banyard, A.C.; McElhinney, L.M.;
de Lamballerie, X.; Müller, T.; Fooks, A.R.; et al. Complete Genomic Sequence of Lleida bat Lyssavirus.
Genome Announc. 2017, 5, e01427-16. [CrossRef] [PubMed]
31. De Benedictis, P.; Minola, A.; Rota Nodari, E.; Aiello, R.; Zecchin, B.; Salomoni, A.; Foglierini, M.; Agatic, G.;
Vanzetta, F.; Lavenir, R.; et al. Development of broad-spectrum human monoclonal antibodies for rabies
post-exposure prophylaxis. EMBOMol. Med. 2016, 8, 407–421. [CrossRef] [PubMed]
32. Ghildyal, R.; Li, D.; Peroulis, I.; Shields, B.; Bardin, P.G.; Teng, M.N.; Collins, P.L.; Meanger, J.; Mills, J.
Interaction between the respiratory syncytial virus G glycoprotein cytoplasmic domain and the matrix
protein. J. Gen. Virol. 2005, 86, 1879–1884. [CrossRef] [PubMed]
33. Enami, M.; Enami, K. Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the
membrane association of the matrix protein. J. Virol. 1996, 70, 6653–6657. [PubMed]
34. Lyles, D.S.; McKenzie, M.; Parce, J.W. Subunit interactions of vesicular stomatitis virus envelope glycoprotein
stabilized by binding to viral matrix protein. J. Virol. 1992, 66, 349–358. [PubMed]
35. Mebatsion, T.; Weiland, F.; Conzelmann, K.K. Matrix protein of rabies virus is responsible for the assembly
and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol.
1999, 73, 242–250. [PubMed]
36. Genz, B.; Nolden, T.; Negatsch, A.; Teifke, J.P.; Conzelmann, K.K.; Finke, S. Chimeric rabies viruses
for trans-species comparison of lyssavirus glycoprotein ectodomain functions in virus replication and
pathogenesis. Berl. Munch. Tierarztl. Wochenschr. 2012, 125, 219–227. [PubMed]
37. Finke, S.; Conzelmann, K.K. Dissociation of rabies virus matrix protein functions in regulation of viral RNA
synthesis and virus assembly. J. Virol. 2003, 77, 12074–12082. [CrossRef] [PubMed]
38. Shimizu, K.; Ito, N.; Mita, T.; Yamada, K.; Hosokawa-Muto, J.; Sugiyama, M.; Minamoto, N. Involvement
of nucleoprotein, phosphoprotein, and matrix protein genes of rabies virus in virulence for adult mice.
Virus Res. 2007, 123, 154–160. [CrossRef] [PubMed]
39. Kuzmin, I.V.; Franka, R.; Rupprecht, C.E. Experimental infection of big brown bats (Eptesicus fuscus) with
West Caucasian bat virus (WCBV). Dev. Biol. (Basel) 2008, 131, 327–337. [PubMed]
40. Banyard, A.C.; Healy, D.M.; Brookes, S.M.; Voller, K.; Hicks, D.J.; Nunez, A.; Fooks, A.R. Lyssavirus infection:
‘low dose, multiple exposure’ in the mouse model. Virus Res. 2014, 181, 35–42. [CrossRef] [PubMed]
41. Turmelle, A.S.; Jackson, F.R.; Green, D.; McCracken, G.F.; Rupprecht, C.E. Host immunity to repeated rabies
virus infection in big brown bats. J. Gen. Virol. 2010, 91, 2360–2366. [CrossRef] [PubMed]
42. Johnson, N.; Vos, A.; Neubert, L.; Freuling, C.; Mansfield, K.L.; Kaipf, I.; Denzinger, A.; Hicks, D.; Nunez, A.;
Franka, R.; et al. Experimental study of European bat lyssavirus type-2 infection in Daubenton’s bats
(Myotis daubentonii). J. Gen. Virol. 2008, 89, 2662–2672. [CrossRef] [PubMed]
Viruses 2018, 10, 130 11 of 11
43. Freuling, C.; Vos, A.; Johnson, N.; Kaipf, I.; Denzinger, A.; Neubert, L.; Mansfield, K.; Hicks, D.; Nunez, A.;
Tordo, N.; et al. Experimental infection of serotine bats (Eptesicus serotinus) with European bat lyssavirus
type 1a. J. Gen. Virol. 2009, 90, 2493–2502. [CrossRef] [PubMed]
44. Franka, R.; Johnson, N.; Muller, T.; Vos, A.; Neubert, L.; Freuling, C.; Rupprecht, C.E.; Fooks, A.R.
Susceptibility of North American big brown bats (Eptesicus fuscus) to infection with European bat lyssavirus
type 1. J. Gen. Virol. 2008, 89, 1998–2010. [CrossRef] [PubMed]
45. Seif, I.; Coulon, P.; Rollin, P.E.; Flamand, A. Rabies Virulence: Effect on pathogenicity and sequence
characterisation of rabies virus mutations affaecting antigenic site III of the glycoprotein. J. Virol. 1985, 53,
926–934. [PubMed]
46. Mebatsion, T. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain
binding site in the P protein and replacing Arg333 in the G protein. J. Virol. 2001, 75, 11496–11502. [CrossRef]
[PubMed]
47. Faber, M.; Faber, M.L.; Papaneri, A.; Bette, M.; Weihe, E.; Dietzschold, B.; Schnell, M.J. A single amino acid
change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J. Virol. 2005,
79, 14141–14148. [CrossRef] [PubMed]
48. Ito, H.; Minamoto, N.; Watanabe, T.; Goto, H.; Rong, L.T.; Sugiyama, M.; Kinjo, T.; Mannen, K.; Mifune, K.;
Konobe, T.; et al. A unique mutation of glycoprotein gene of the attenuated RC-HL strain of rabies virus,
a seed virus used for production of animal vaccine in Japan. Microbiol. Immunol. 1994, 38, 479–482. [CrossRef]
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
